Buparlisib and Ponatinib Inhibit Aggressiveness of Cholangiocarcinoma Cells Via Suppression of IRS1-related Pathway by Targeting Oxidative Stress Resistance
Biomedicine & Pharmacotherapy(2024)
Key words
Bile duct cancer,Targeted therapy,Buparlisib,Ponatinib,Anti-cancer,Insulin receptor substrate 1
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined